RETRACTED ARTICLE: Testing alternatives: the use of adipose-derived mesenchymal stem cells to slow neurodegeneration in a rat model of Parkinson’s disease

Meligy, Fatma Y.; Elgamal, Dalia A.; Allah, Eman S.H. Abd; Idriss, Naglaa K.; Ghandour, Nagwa; Bayoumy, Ehab M R; Khalil, Azza Sayed Abdelrehim; Fiky, Mohamed M El; El-Khashab, Mostafa

doi:10.1007/s11033-019-05018-9

Cited by 13 publications

(8 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic infusion of human MSCs in rat PD disorders reduced uncoordinated limb movement measured in behavioral tests. [ 107,108 ] It was associated with elevated dopamine levels in the striatum of MSC recipients and an increased number of tyrosine hydroxylase (TH)‐positive dopaminergic neurons, suggesting a regenerative effect of MSC. Similarly, direct striatal injection of MSCs in rodent models of PD improved locomotor activity, enhanced neurogenesis, and induced neuroblast migration.…”

Section: Experimental Attempts To Use Mesenchymal Stem Cells In the Tmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stem Cells for Neurological Disorders

et al. 2021

View full text Add to dashboard Cite

Neurological disorders are becoming a growing burden as society ages, and there is a compelling need to address this spiraling problem. Stem cell‐based regenerative medicine is becoming an increasingly attractive approach to designing therapies for such disorders. The unique characteristics of mesenchymal stem cells (MSCs) make them among the most sought after cell sources. Researchers have extensively studied the modulatory properties of MSCs and their engineering, labeling, and delivery methods to the brain. The first part of this review provides an overview of studies on the application of MSCs to various neurological diseases, including stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, and other less frequently studied clinical entities. In the second part, stem cell delivery to the brain is focused. This fundamental but still understudied problem needs to be overcome to apply stem cells to brain diseases successfully. Here the value of cell engineering is also emphasized to facilitate MSC diapedesis, migration, and homing to brain areas affected by the disease to implement precision medicine paradigms into stem cell‐based therapies.

show abstract

Section: Experimental Attempts To Use Mesenchymal Stem Cells In the Tmentioning

confidence: 99%

“…[ 117,118 ] MSC infusion decreased gene expression of GFAP in venous blood of the rat model of PD and reduced microglial activation. [ 108 ] Adipose‐derived MSCs transplanted in a rat model of PD upregulated peripheral anti‐inflammatory cytokines. [ 111 ]…”

Section: Experimental Attempts To Use Mesenchymal Stem Cells In the Tmentioning

confidence: 99%

Mesenchymal Stem Cells for Neurological Disorders

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Meligy et al studied a rotenone-induced rat model of Parkinson's disease to demonstrate that ADSC-EVs significantly increased levels dopamine in the treatment group compared to the control (Meligy et al, 2019). In contrast to the overexpression of GFAP seen in animals treated with ADSCs (Clairembault et al, 2014), it was shown that ADSC-EVs markedly decreased the gene expression of GFAP, restored astrocytic injury, and improved motor performance in their Parkinson's disease model (Meligy et al, 2019). This suggested that GFAP may play a different role in neuroprotection in the same model whether treated with ADSCs or ADSC-EVs.…”

Section: Exosomes In the Treatment Of Neurological Diseasesmentioning

confidence: 99%

Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration

et al. 2020

View full text Add to dashboard Cite

“…For these reasons, therapy using MSCs in a PD animal model has been attempted. In experimental studies, rat BM-MSC administration has resulted in improvements in motor functions in PD animal models [ 121 , 122 ], and other studies have shown that these results are associated with elevated dopamine levels in the striatum, enhanced neurogenesis, inhibited transmission of alpha-synuclein, and immunomodulatory effects [ 122 – 125 ]. A study has also shown that the preconditioning of BM-MSCs is more effective [ 126 ].…”

Section: Application Of Hbm-mscs In Neurological Diseasesmentioning

confidence: 99%

Strategies to Improve the Quality and Freshness of Human Bone Marrow-Derived Mesenchymal Stem Cells for Neurological Diseases

Lee

Kwon

et al. 2021

Stem Cells International

View full text Add to dashboard Cite

Human bone marrow-derived mesenchymal stem cells (hBM-MSCs) have been studied for their application to manage various neurological diseases, owing to their anti-inflammatory, immunomodulatory, paracrine, and antiapoptotic ability, as well as their homing capacity to specific regions of brain injury. Among mesenchymal stem cells, such as BM-MSCs, adipose-derived MSCs, and umbilical cord MSCs, BM-MSCs have many merits as cell therapeutic agents based on their widespread availability and relatively easy attainability and in vitro handling. For stem cell-based therapy with BM-MSCs, it is essential to perform ex vivo expansion as low numbers of MSCs are obtained in bone marrow aspirates. Depending on timing, before hBM-MSC transplantation into patients, after detaching them from the culture dish, cell viability, deformability, cell size, and membrane fluidity are decreased, whereas reactive oxygen species generation, lipid peroxidation, and cytosolic vacuoles are increased. Thus, the quality and freshness of hBM-MSCs decrease over time after detachment from the culture dish. Especially, for neurological disease cell therapy, the deformability of BM-MSCs is particularly important in the brain for the development of microvessels. As studies on the traditional characteristics of hBM-MSCs before transplantation into the brain are very limited, omics and machine learning approaches are needed to evaluate cell conditions with indepth and comprehensive analyses. Here, we provide an overview of hBM-MSCs, the application of these cells to various neurological diseases, and improvements in their quality and freshness based on integrated omics after detachment from the culture dish for successful cell therapy.

show abstract

RETRACTED ARTICLE: Testing alternatives: the use of adipose-derived mesenchymal stem cells to slow neurodegeneration in a rat model of Parkinson’s disease

Cited by 13 publications

References 67 publications

Mesenchymal Stem Cells for Neurological Disorders

Mesenchymal Stem Cells for Neurological Disorders

Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration

Strategies to Improve the Quality and Freshness of Human Bone Marrow-Derived Mesenchymal Stem Cells for Neurological Diseases

Contact Info

Product

Resources

About